Compare Crispr Therapeutics AG (CRSP) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs ProShares UltraPro S&P500 — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while ProShares UltraPro S&P500 trades at $155.11. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | UPRO | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $76.78 | $155.10 |
52-Week Low | $44.34 | $89.29 |
Enterprise Value | $3.65B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
UPRO, a leveraged ETF tracking the S&P 500, trades at $154.9 with a slight 0.06% decline. Technical indicators show a bullish trend with strong moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. Support lies at $152, with resistance at $155. Recent news highlights institutional buying and S&P 500 volatility amid inflation data and AI-driven earnings optimism.
The outlook for UPRO hinges on S&P 500 momentum, with bullish technicals but overbought risks. Upside potential exists if the index breaks resistance, but high leverage amplifies losses during pullbacks. Key risks include market volatility, inflation concerns, and stretched valuations. Investors should weigh the ETF's leveraged structure against broader market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
